Reprint

PET/CT Imaging in Oncology: Clinical Updates and Perspectives

Edited by
November 2023
180 pages
  • ISBN978-3-0365-9450-7 (Hardback)
  • ISBN978-3-0365-9451-4 (PDF)

This book is a reprint of the Special Issue PET/CT Imaging in Oncology: Clinical Updates and Perspectives that was published in

Medicine & Pharmacology
Public Health & Healthcare
Summary

This reprint focuses on the most recent advances in PET/CT imaging within the field of oncology. These innovations include studies on novel or experimental tracers, such as [18F]FES for the imaging of advanced breast cancer and [68Ga]Ga-Nitroimidazole for visualizing hypoxic tumour components; research on new radiopharmaceuticals represents, in fact, one the most important study fields of PET research. Advanced image analysis, such as radiomics, is also featured in this reprint; this method has been applied to both traditional nuclear medicine clinical issues, such as thyroid nodules, as well as in the setting of new therapeutic approaches, such as CAR-T cell therapy. Finally, the theranostic implications of PET radiotracers and the diagnostic processes of rare tumours are explored in this reprint.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
thyroid incidentalomas; radiomics; texture analysis; 18F-FDG; PET/CT; positron emission tomography; thyroid cancer; cervical cancer; hypoxia; 68Ga-Nitroimidazole; 18F-FDG; HIF-1α; immunohistochemistry; Mantle Cell Lymphoma; PET/CT; MTV; TLG; sarcopenia; 18F-FDG; diffuse-large B cell lymphoma; chimeric antigen receptor T cells; response assessment; positron emission tomography; computed tomography; texture analysis; paraneoplastic syndromes; neurooncology; [18F]FDG PET/CT; PNS; PET/CT; FDG; FES; breast cancer; oestrogen receptor; diagnosis; nuclear medicine; meningioma; peptide receptor radionuclide therapy; PRRT; targeted therapy; somatostatin receptor; SSTR; n/a; solitary fibrous tumor; hemangiopericytoma; PET/CT; fluorodeoxyglucose; fluorocholine; non-FDG radiopharmaceuticals; [18F]FDG PET/MRI; multiparametric imaging; dual-time-point kinetic; cervical carcinoma; lymph node metastases; PSMA hybrid imaging; staging of primary prostate cancer; [18F]PSMA-1007; [68Ga]Ga-PSMA-11; SUVmax cut-off level; prostate carcinoma; intra-tumoural heterogeneity; intrahepatic cholangiocarcinoma; positron emission tomography–computed tomography; immunology; FGFR2 translocation; imaging fusion; navigation technology; immunotherapy; Hodgkin lymphoma; FDG-PET; pseudoprogression; LYRIC; MTV; whole-body; dynamic PET; parametric FDG; Patlak; FDG; PET/CT